Pliant Therapeutics price target lowered to $1.50 from $4 at Citi
Citi lowered the firm’s price target on Pliant Therapeutics (PLRX) to $1.50 from $4 and keeps a Neutral rating on the shares. The company ...
Pliant Therapeutics Shares it 52-Week Low After Phase2b Trial Discontinued
Pliant Therapeutics shares dropped 52% to $1.64, after the company said it was discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis. The stock hit its 52-week ...
Hosted on MSN4h
Pliant Therapeutics Reports Q4 2024 Results and Updates
Pliant Therapeutics, Inc. ( ($PLRX) ) has released its Q4 earnings. Here is a breakdown of the information Pliant Therapeutics, Inc. presented to ...
RBC Capital Reaffirms Their Hold Rating on Pliant Therapeutics (PLRX)
RBC Capital analyst Brian Abrahams maintained a Hold rating on Pliant Therapeutics (PLRX – Research Report) yesterday and set a price target of ...
Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder
Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...
ENDPOINTS NEWS15h
Pli­ant calls it quits on Phase 2b id­io­path­ic pul­monary fi­bro­sis study
Pliant Therapeutics discontinues Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis due to safety concerns, but ...
Fintel on MSN21d
JP Morgan Downgrades Pliant Therapeutics (PLRX)
Fintel reports that on February 10, 2025, JP Morgan downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from Overweight to Neutral. Analyst Price Forecast Suggests 1,212.38% Upside As of ...
Pliant Therapeutics (PLRX) Projected to Post Earnings on Tuesday
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) is anticipated to issue its quarterly earnings data before the market ...
MedCity News22d
Pliant Therapeutics Presses Pause on Clinical Trial for Lung Disorder Drug
A clinical study testing a Pliant Therapeutics drug once considered a promising prospect for treating a fatal lung disorder is now on pause at the recommendation of independent outside observers.
Pliant Therapeutics reinstated with a Neutral at Cantor Fitzgerald
Cantor Fitzgerald reinstated coverage of Pliant Therapeutics (PLRX) with a Neutral rating and no price target The company is discontinuing the ...